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ABSTRACT: Amino acids are of paramount importance as chiral building blocks of
life, for drug development in modern medicinal chemistry, and for the manufacture of
industrial products. In this work, the stereoselective synthesis of (S)- and (R)-2-amino-
4-hydroxybutanoic acid was accomplished using a systems biocatalysis approach
comprising a biocatalytic one-pot cyclic cascade by coupling of an aldol reaction with
an ensuing stereoselective transamination. A class II pyruvate aldolase from E. coli,
expressed as a soluble fusion protein, in tandem with either an S- or R-selective,
pyridoxal phosphate dependent transaminase was used as a catalyst to realize the
conversion, with formaldehyde and alanine being the sole starting materials.
Interestingly, the class II pyruvate aldolase was found to tolerate formaldehyde
concentrations of up to 1.4 M. The cascade system was found to reach product
concentrations for (S)- or (R)-2-amino-4-hydroxybutanoic acid of at least 0.4 M,
rendering yields between 86% and >95%, respectively, productivities of >80 g L−1 d−1, and ee values of >99%.
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■ INTRODUCTION
Amino acids are compounds of paramount importance for
living organisms, as building blocks for protein and peptide
synthesis, chiral intermediates in modern medicinal chemistry,
and valuable building blocks in the manufacture of industrial
products.1 An interesting example is 2-amino-4-hydroxybuta-
noic acid (i.e., homoserine), a noncanonical amino acid
homologous to L-serine by insertion of an additional methylene
unit into the side chain and an important metabolic
intermediate.2 It also constitutes a valuable building block for
the synthesis of 3-hydroxypropionic acid and 1,3-propanediol,
important starting materials in the manufacture of biocompat-
ible plastic and polytrimethylene terephthalate (PTT), among
other industrial products.3 Furthermore, L-homoserine lactone
derivatives are useful compounds for studying the quorum
sense signaling (QSS) mechanism (i.e., cell to cell communi-
cation) and indeed as potential QSS inhibitors in new
antimicrobial strategies against pathogenic Gram-negative and
Gram-positive bacteria (antivirulence intervention strategy).1c,4
The industrial production of amino acids, including L-
homoserine, has to date predominantly been achieved via
microbial fermentation (i.e., cell factories).2c,e,3b,5 However,
drawbacks of this technology include the unpredictable
physiological behavior of cellular production systems upon
engineering of elusive metabolic pathways and a rather limited
ﬂexibility toward the synthesis of structurally diverse non-
natural products.6 In contrast, isolated enzyme systems for in
vitro production (i.e., systems biocatalysis)6 oﬀer simplicity and
adaptability, because these are unrestrained by problems arising
from the intricate nature of cellular metabolic pathways. In
addition, such systems beneﬁt from the ever-increasing number
and diversity of available native enzymes, as well as their
engineered variants, active toward a broad variety of substrate
analogues. From a practical point of view, in vitro systems are
easier to manage and monitor because of their lower
complexity.5b,6,7 Needless to say, the concept of systems
biocatalysis shares all the synthetic and environmental
advantages that have become the hallmark of commercial
biocatalytic processes.
■ RESULTS AND DISCUSSION
A stereoselective biocatalytic one-pot cascade methodology8
was envisioned for the synthesis of both enantiomeric forms of
homoserine (S-5 and R-5), comprising cyclic aldol addition and
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subsequent reductive amination reactions, with eﬀective
pyruvate (2) recycling (Scheme 1): (i) aldol addition of 2 to
formaldehyde (1); (ii) reductive amination of aldol adduct 3,
using alanine (S-4 or R-4) as the amine donor, to produce S-5
or R-5, respectively, with concomitant release of 2, to be
recycled by recurrent aldol addition, thus favoring the reductive
amination equilibrium toward 5. Notably, by applying such a
synthetic cycle the approach can be implemented with readily
available and inexpensive substrates (in this example, alanine
and formaldehyde), while requiring just catalytic amounts of
pyruvate to trigger the overall pathway.
A viable commercial process requires an aldolase tolerating
high concentrations of aldehyde substrates, which are strongly
electrophilic, a transaminase that is active and selective under
similar reaction conditions, and cost eﬀectiveness for the overall
biotransformation.
Biochemical studies have been reported for the in vitro
enzymatic aldol addition of pyruvate to formaldehyde using a
mammalian hydroxyoxobutyrate aldolase (EC 4.1.2.1), which is
a class I aldolase that acts via covalent substrate activation by
Schiﬀ base formation at a lysine residue in the active site.9
However, such enzymes easily become inactivated by non-
speciﬁc reactions involving the essential lysine residue in the
presence of strong electrophiles, such as formaldehyde, even at
low concentrations.10 In contrast, class II pyruvate aldolases
utilize a divalent metal ion as an essential cofactor to promote
the enolization of the pyruvate nucleophile and do not possess
a sensitive active-site lysine and thus appear potentially more
suitable for the target reaction.11 Among them, YfaU (EC
4.1.2.53) was selected from the genome of E. coli K-12.12 YfaU
is known to catalyze the reversible cleavage of pyruvate from 2-
keto-3-deoxy-L-rhamnonate, 2-keto-3-deoxy-L-lyxonate, and 4-
hydroxy-2-ketopentanoic acid to furnish L-lactaldehyde, hydrox-
yethanal, and ethanal, respectively. Nevertheless, hitherto
reported studies regarding this enzyme concern fundamental
biochemical studies only with little or no direct connection to
any potential synthetic utility.12 The rhmA gene encoding the
YfaU protein was initially cloned in the pQE40 expression
vector (Qiagen) to generate a fusion protein with very soluble
dihydrofolate reductase (DHFR) at the N terminus.13
However, under these conditions it was found that DHFR-
YfaU was mostly expressed as insoluble inclusion bodies
(Figure S2A in the Supporting Information). This problem was
circumvented by expressing YfaU as a fusion protein with
maltose binding protein (MBP) from E. coli at the N terminus
(MBP-YfaU), along with a His6 tag for aﬃnity puriﬁcation
(Figure S2B) (yield 180 mg L−1 of MBP-YfaU of bacterial
growth medium). While the structure of native YfaU is
hexameric (a trimer of dimers, the dimer being the minimal
repetitive unit),12a the MBP-YfaU fusion protein only forms a
dimer, as determined by gel ﬁltration (see the Supporting
Information). It appears that the MBP fusion prevented the
hexameric biological assembly but not functional dimer
formation. Recombinant MBD-YfaU apparently exhibited a
high aﬃnity for its natural Mg2+ cofactor from the bacterial
growth medium, which predominantly remained bound in the
active site even subsequent to puriﬁcation via IMAC and
dialysis against 10 mM Na+ phosphate buﬀer, pH 7.0 (MBP-
YfaU(Mg2+) 2.5 U mg−1; see Table S1 in the Supporting
Information).
NMR data conﬁrmed that the enzymatic aldol addition of 2
to 1 yielded the desired intermediate 3. Remarkably, when the
best reaction conditions were screened for the critical
carboligation step, MBP-YfaU(Mg2+) retained activity at
substrate concentrations of >1 M for both 1 and 2 (IC50[1]
= 1.4 M) (Figure 1), leading to an outstanding productivity of
140 g L−1 d−1 of intermediate 3 at [1] = [2] = 1 M even under
preliminary nonoptimized conditions. This observation was
very surprising, given that strongly electrophilic aldehydes such
as 1 often denature enzymes even at low concentration.
Incubation with other divalent cations showed that MBP-
YfaU as a ligand with Co2+ or Ni2+ exhibited ∼3- or 2-fold
higher activity (see Table S1 and accompaying discussion in the
Supporting Information), respectively. As observed for other
class II aldolases, some nonphysiological metals, particularly
Co2+ and Ni2+, can improve the activity and/or even catalyze
side reactions by taking advantage of the reactive intermediates
generated by the catalytic machinery.12a,14 No product
formation was observed in control experiments performed
under the same conditions without enzyme or in the presence
of EDTA. Control reactions using bovine serum albumin as a
noncatalytic protein in the presence of Mg2+ or Ni2+ resulted in
a background level of <0.5% conversion after 24 h.
Scheme 1. One-Pot Biocatalytic Cascade Synthesis of S-5 or
R-5 with Substrate Recycling, Starting from Formaldehyde
(1) and S-4 or R-4, Respectivelya
aAbbreviations: PyvA, pyruvate aldolase; TA, S- or R-selective
transaminase.
Figure 1. Inﬂuence of the concentration of 1 on the yield of 3 in the
aldol addition of 2 to 1 catalyzed by MBP-YfaU(Mg2+). Conditions:
[2] = [1], 50 mM Na+ phosphate buﬀer, pH 7.0, and 24 h of reaction
(experimental details are given in the Supporting Information).
ACS Catalysis Research Article
DOI: 10.1021/acscatal.6b03181
ACS Catal. 2017, 7, 1707−1711
1708
In addition, the formation of the byproduct 6 was also
observed (Scheme 2), which arose from the subsequent
addition of product 3 to a second equivalent of 1. For example,
under batch conditions, with a 1:1 molar ratio of substrates and
MBP-YfaU(Mg2+) as biocatalyst (speciﬁc conditions: [2] = [1]
= 1 M, 50 mM Na+ phosphate buﬀer, pH 7, MBP-YfaU(Mg2+)
(31 mg, 77 U, 10 U mL−1) and 24 h of reaction at 25 °C), a
mixture of 3 and 6 in a ratio of 9:1 (by NMR analysis) was
observed. Interestingly, it was found that this side reaction was
mainly catalyzed by Ni2+ and Co2+ ions themselves, with no 6
produced with just Mg2+ present (Figure S7 in the Supporting
Information). However, MBP-YfaU(Mg2+) did catalyze the
secondary reaction, but to a much lower extent (<10%) (Figure
S6 in the Supporting Information). Thus, MBP-YfaU(Mg2+ or
Zn2+) species were the most selective biocatalysts toward the
synthesis of 3 (Figure S6), with the former being selected for
the purpose of this work.
The next step was the stereoselective enzymatic reductive
amination of 3 (Scheme 1). To this end, we screened a library
of 51 individual pyridoxal phosphate (PLP) dependent
transaminases, provided by Prozomix Ltd. as lyophilized
crude cell free extracts, using S-4 and R-4 as amine donors
(Figure 2). From the best hits showing high conversion rates
(i.e., >80% after 24 h; Figure 2), enzyme TA51 from Vibrio
ﬂuvialis (ee > 99%) was selected for further studies. The
thermodynamic equilibrium constant for the desired reaction
was 0.77 (see the Supporting Information), which compares
favorably with other enzymatic reductive aminations.8a,15
With a suitable transaminase identiﬁed, we next investigated
the optimal [2] required for eﬀective substrate cycling within
the biocatalytic cascade (Scheme 1 and Figure S10 in the
Supporting Information). To trigger the biocatalytic cascade, in
principle the initial amount of 2 should be kept low to
overcome the thermodynamic limitations of the reductive
amination. Indeed, a reaction comprising ≤0.05 mmol of 2, 0.1
mmol of S-4, portionwise addition of 1 (0.1 mmol, 0.0125
mmol h−1, eight additions), MBP-YfaU(Mg2+) (10 U), and
TA51 (2.8 U) successfully demonstrated the recycling of 2 as
the deaminated component produced in the transamination.
We next observed that the lower the pyruvate to alanine ratio
2:S-4 (e.g., ≤0.5) chosen, the lower the amount of 1 tolerated
by the system in each addition (Figure 3). Presumably,
inhibitory or inactivation eﬀects are the most plausible
explanation, as indicated by the experiments conducted ad
hoc (Figure S11 in the Supporting Information). However,
reducing the amount of 1 was also found to be detrimental,
presumably because of the thermodynamic limitations for the
reductive amination that are caused by an excess of unreacted
pyruvate.
A kinetic analysis of the compounds that participate in the
cascade starting from 2, S-4, and 1 (Figure 4) indicates that (a)
the ﬁrst additions of 1 were rapidly converted to 3, consuming
the starting quantity of pyruvate, (b) S-5 was ﬁrst detected
when the aldol adduct reached a level of ∼50 mM (0.05 mmol),
(c) after that stage, there is an eﬀective recycling of 2, which
favors conversion toward the thermodynamic equilibrium and
minimizes TA inactivation by 1, (d) 3 accumulated to a ﬁnal
concentration of ∼200 mM (0.2 mmol), and (e) under these
conditions a 75% yield of S-5 was achieved. Lower yields were
obtained (Figure S12A,B in the Supporting Information) when
Scheme 2. Sequential Catalysis by MBP-YfaU(Mg2+) and
Ni2+ or Co2+ in the Aldol Addition of 2 to 1 and Subsequent
Aldol Addition of 3 to a Second Equivalent of 1 To Yield 6
Figure 2. Screening of transaminases (Prozomix) for the reductive
amination of 3 to S-5 (blue) and R-5 (red) at 24 h (full conditions are
given in the Supporting Information). TA51 corresponds to
transaminase from Vibrio ﬂuvialis (supplied by Prozomix Ltd.).
Figure 3. Eﬀect of the total amount of 1 added on S-5 formed at 24 h
and at diﬀerent 2:S-4 ratios. Conditions: S-4 (0.1 mmol), 1 added
portionwise (0.0125−0.1 mmol h−1, eight additions), with MBP-
YfaU(Mg2+) and TA51 as biocatalysts. V = 1 mL.
Figure 4. Progress of the biocatalytic cyclic cascade synthesis of S-5
with 1 added portionwise. Conditions: 2 (0.2 mmol), S-4 (0.4 mmol),
1 (12 additions of 0.05 mmol at 1 h intervals, total 0.6 mmol), MBP-
YfaU(Mg2+) (4 mg, 10 U), and TA51 (20 mg, 2.8 U) in 50 mM Na+
phosphate buﬀer, pH 7.0, V = 1 mL. Samples were taken immediately
before the addition of 1. Dashes indicate the cumulative addition of 1.
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less 1 was employed; when a cumulative 0.2 mmol of 1 was
added (i.e., eﬀectively performing a one-pot, two-step process
with no pyruvate recycling) during a 4 h reaction, the yield fell
to just 30%, whereas with a cumulative 0.4 mmol of 1 over 8 h,
the yield was reduced to 56%.
We further tried to optimize the system by investigating the
eﬀect of continuous feeding of 1, using a syringe pump, on the
yield of S-5 when using transaminases TA20, TA26, TA39, and
TA51 (Table 1). Remarkably, when TA39 was used, the yield
of S-5 increased to 86% (ee > 99% by chiral HPLC) with a
cumulative formaldehyde addition of 8.4 mmol (Figure 5),
implying a net quantity of 3 mmol of pyruvate recycled, given
that the ﬁnal amount of 2 was just 0.06 mmol. To further
demonstrate the utility of this system, the synthesis of R-5 was
also accomplished in near quantitative yields (ee > 99%) when
TA7, TA17, or TA43 was employed in the presence of R-4 as
the amine donor.
■ CONCLUSION
In summary, we have developed a biocatalytic one-pot cyclic
cascade system for the complementary, stereoselective synthesis
of both L- and D-homoserine in 86% and >95% yields,
respectively, with >99% ee each. Diﬀerences in the product
yields observed could be due to distinct inhibition/deactivation
of the transaminases involved in the reaction. Readily available
inexpensive starting materials such as formaldehyde and alanine
can be used at high concentrations (i.e., 0.8 M), leading to
homoserine productivities of >80 g L−1 d−1 under proof of
concept conditions. This compares favorably with reported
fermentation processes that provide only between 2.9 and 6.4 g
L−1 d−1 of product.16 The system comprises a simple
combination of biocatalytic aldol addition and reductive
amination reactions working in tandem, by using the class II
pyruvate aldolase MBP-YfaU(Mg2+) from E. coli K12 and an
appropriate S- or R-selective PLP-dependent transaminase
available from Prozomix. Plausibly, this systems biocatalysis
concept should be applicable to related pyruvate derived
products by using other aldehyde acceptors for the synthesis of
a large variety of other amino acids and related useful building
blocks. Research toward this end is currently underway in our
laboratories.
■ EXPERIMENTAL SECTION
Biocatalytic Cyclic Cascade Synthesis of L-Homoser-
ine. The reaction was carried out in a Falcon tube (50 mL).
Initial amounts of pyruvate (2.1 mmol) and L-Ala (4.2 mmol)
were dissolved in 50 mM Na+ phosphate buﬀer, pH 7.0,
containing PLP (1 mM). Then, MBP-YfaU(Mg2+) (105 U, 10
U mL−1 in the ﬁnal reaction) and Prozomix TA39 (74 U, 7 U
mL−1 in the ﬁnal reaction) were added. After that, form-
aldehyde was constantly added with a syringe pump at 0.57
mmol h−1 (0.18 mL h−1) over 15 h (representing a cumulative
addition of 8.4 mmol). The starting reaction volume was 7.8
mL, and the ﬁnal volume was 10.5 mL. Transformation to Cbz-
L-homoserine lactone and puriﬁcation and characterization
procedures are described in the Supporting Information.
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Table 1. Biocatalytic Cyclic Cascade System for S-5 and R-5
Synthesisa
Prozomix TA TA/Ud 5/% isolated yieldb/% ee/%c
TA20 12 npde
TA26 34 11 nif ndg
TA39 7 86 56 >99 (S)
TA51 28 64 29 >99 (S)
TA7 480 >95 64 >99 (R)
TA17 1160 >95 59 >99 (R)
TA43 460 >95 63 >99 (R)
aConditions: 2 (2.1 mmol) and S-4 (4.2 mmol) in 50 mM Na+
phosphate buﬀer, pH 7.0 (7.8 mL), PLP (10.5 μmol), MBP-
YfaU(Mg2+) (40 mg, 100 U), TA (as in the table), and 1 continuously
added with a syringe pump (0.57 mmol h−1, 0.18 mL h−1; total added
1 8.4 mmol during 15 h), reaction time 24 h, V = 10.5 mL (detailed
conditions are given in the Supporting Information). bThe products
were isolated as Cbz-L- and Cbz-D-homoserine lactone (S-7 and R-7,
respectively; see the Supporting Information). cDetermined by chiral
HPLC (see the Supporting Information). dFor unit deﬁnition of TA
see the Supporting Information. enpd: no product detected. fni: not
isolated. gnd: not determined.
Figure 5. Biocatalytic cyclic cascade system for S-5 synthesis with
continuous addition of 1: eﬀect of total 1 added on the reaction
mixture composition after 24 h. Conditions: 2 (2.1 mmol), S-4 (4.2
mmol), PLP (10.5 μmol), MBP-YfaU(Mg2+) (40 mg, 100 U), TA39
(210 mg, 7.4 U), 1 continuously added with a syringe pump (0.57
mmol h−1, 0.18 mL h−1, and duration 4−15 h depending on the
experiment), V = 10.5 mL (complete experimental details are given in
the Supporting Information).
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